January 1988

Uses of Carbamazepine for Psychiatric Disorders: A Review

Edward Kim, MD
Jefferson Medical College, Philadelphia PA

Follow this and additional works at: https://jdc.jefferson.edu/jeffjpsychiatry
Part of the Psychiatry Commons
Let us know how access to this document benefits you

Recommended Citation
DOI: https://doi.org/10.29046/JJP.006.2.008
Available at: https://jdc.jefferson.edu/jeffjpsychiatry/vol6/iss2/10
Uses of Carbamazepine for Psychiatric Disorders: A Review

Edward Kim, M.D.

INTRODUCTION

Carbamazepine, first synthesized in 1953, was initially marketed in Europe as an anticonvulsant. In 1971 Dalby reported the drug’s psychotropic effects, most notably mood stabilization, in patients with temporal lobe epilepsy (TLE) (1). Other psychiatric applications such as the treatment of affectively and behaviorally labile patients are being explored. These studies are yielding data relevant to the treatment and understanding of the neurobiology of mental illness. For this reason, familiarity with carbamazepine is becoming increasingly important to psychiatrists.

CHEMISTRY AND PHARMACOLOGY

Carbamazepine is structurally similar to the tricyclic antidepressant imipramine (Fig. 1) (2,3). Plasma levels peak four to eight hours after ingestion, with 75% of the drug bound to plasma proteins. CSF levels are dependent on the level of unbound drug in plasma. Metabolism occurs primarily in the liver via the cytochrome P-450 oxidase system, producing carbamazepine-10,11-epoxide which is as active and may reach levels up to half that of carbamazepine. This is almost entirely converted to carbamazepine-trans-10,11-dihydrodiol by epoxide hydrolase before excretion in the urine (Fig 2) (4). The epoxide is 50% protein-bound in plasma (5).

Carbamazepine induces hepatic enzymes, thus enhancing its own metabolism. Therefore, the 30-hour half-life of a single oral dose drops to 20 hours at three weeks at 12 hours after several months. The half-life is reduced in patients who simultaneously take other inducers of hepatic enzymes such as phenobarbital, phenytoin, or alcohol (4). Carbamazepine also enhances the metabolism of phenytoin and warfarin for the same reason (6).

CLINICAL GUIDELINES

The most common side effect is an allergic skin rash which occurs in 5% to 15% of treated patients (7). This may be accompanied by sore throat, mucosal ulceration and low grade fever. Antihistamines can be effective in eliminating
allergic symptoms, though the rash may require discontinuation of carbamazepine. Carbamazepine-induced agranulocytosis has received much attention because of its mortality rate of up to 50%. However, less than thirty cases have been reported (2). This idiosyncratic reaction has a prevalence of one in 20,000 to 40,000 and is unrelated to a harmless 25% decrease in white cell count which is fairly common (7). About 10% of patients receiving the drug develop a mild dose-related leukopenia which resolves within the first four months. Of these, approximately 2% continue with a persistent leukopenia which necessitates discontinuation of therapy (2). Neurotoxic side effects of carbamazepine may include drowsiness, vertigo, ataxia, diplopia, and blurred vision. Patients acutely intoxicated on the drug can exhibit sedation, respiratory depression, hyperirritability, and even seizures. Other side effects include nausea and vomiting, and hepatotoxicity ranging from mild elevation of serum transaminases to acute hepatitis. In addition, chronic administration can also cause a condition resembling the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), with water retention, hyponatremia, and possible water intoxication (2).

The initial dose of carbamazepine in healthy adults is 200 mg once or twice a day. This is increased by no more than 200 mg a day to a total of 200 mg t.i.d. A serum level should be checked after five days and dosage adjusted accordingly (7). The acuity of the patient dictates how aggressively the dosage should be increased, but the appearance of neurotoxicity is a clear indication for smaller, more gradual increments. Maintenance doses average about 1000 mg/day, though the range may vary from 200 to 1600 mg/day (8). In patients who are elderly or have liver disease, dosage and increments should be appropriately decreased. Therapeutic serum levels range from 6–12 μg/ml; neurotoxic side effects are more frequent above 10 μg/ml (2,4). Levels should be checked frequently during initial therapy since 90% of enzyme induction occurs in the
FIGURE 2. Metabolic pathway of carbamazepine. Both the epoxide and dihydrodiol are excreted in the urine.
first month (7). Moreover, a complete blood count and liver panel should be checked prior to and periodically during treatment (2).

NEUROLOGIC AND ENDOCRINE APPLICATIONS

Carbamazepine, a potent anticonvulsant is the drug of choice in temporal lobe epilepsy (9), and a first-line drug in controlling grand mal seizures. It is also effective in the treatment of trigeminal neuralgia and other chronic pain syndromes (10-13). Its antidiuretic properties have led to its use in managing diabetes insipidus (10).

APPLICATIONS IN MOOD DISORDERS

Most psychiatric trials of carbamazepine have been conducted with patients with bipolar disorder, although some studies have included schizoaffective patients in their test groups. Beginning in the early 1970’s Okuma et al (15,16) in Japan demonstrated that carbamazepine is beneficial in the treatment of acutely manic patients and in longterm prophylaxis against mania. In a double-blind controlled study, Post et al (17) at the National Institutes of Mental Health reported carbamazepine’s clear efficacy over placebo in symptom relief in seven out of nine (88%) manic patients. Of these, four (57%) relapsed during placebo administration.

The drug’s acute anti-manic efficacy is approximately that of chlorpromazine (18). In over half of treated patients, peak antimanic effects were reached within ten days of administration of either chlorpromazine or carbamazepine. Carbamazepine also lowered scores on the Clinical Global Impression (CGI) scale on average as much as lithium (19). Lithium, however, had a more consistent anti-manic effect than carbamazepine: the changes in CGI scores tended to cluster around the mean in patients treated with lithium, while the mean CGI change in carbamazepine-treated patients was largely due to a few who responded extremely well. A double-blind 3-year study comparing lithium (n = 27) and carbamazepine (n = 29) found both drugs effective in about two thirds of treated patients (26). Peak symptom relief was reached within three months of treatment onset in both groups. The only striking difference between the drugs was their relative dropout rates. Lithium-treated patients with more schizophrenic or schizoaffective symptoms had a significantly higher dropout rate than carbamazepine-treated patients (50% vs. 20%, respectively). In contrast, patients who demonstrated “classical” bipolar psychotic features had a lower dropout rate when treated with lithium (20% vs. 35%, respectively).

Investigators are attempting to define a population of patients who are particularly responsive to carbamazepine and who, therefore, would be considered prime candidates for this treatment early in their illness. Some patients with a history of lithium resistance responded better when carbamazepine was added to or substituted for lithium (17,21). In two open clinical trials with
bipolar and schizoaffective patients resistant to lithium and/or neuroleptic maintenance (22, 23), a total of 14 out of 21 (67%) of those patients improved when carbamazepine was added or substituted into their treatment regimen. Observations that rapid-cycling bipolar patients respond well to carbamazepine (17, 21, 22, 24) have yet to be demonstrated in controlled clinical trials.

The drug’s therapeutic effect in depressed patients is somewhat less clear, with five of thirteen (38%) bipolar patients showing marked improvement in Post et al’s original report (17), and twelve of thirty-five (34%) showing marked improvement in a subsequent study which involved bipolar (n = 24) and unipolar (n = 11) depressed patients (25). The antidepressant effect is related to plasma levels of the epoxide metabolite rather than carbamazepine itself (26). The drug’s time course of action in depression is similar to that of tricyclic antidepressants (TCA’s), with substantial improvements occurring after two weeks and maximum effect after three weeks (27). Because TCA’s are known to induce more rapid cycling in some bipolar patients treated for depression (28), carbamazepine may be considered as an alternative treatment in patients with a history of rapid cycling or mania during TCA therapy. One depressed bipolar patient with a history of TCA-induced mania despite lithium prophylaxis responded well to carbamazepine without cycling into mania (29). A recent case report described the successful treatment of a bipolar depressed patient using carbamazepine and electroconvulsive therapy (30).

OTHER PSYCHIATRIC APPLICATIONS

Carbamazepine was found to markedly decrease the severity and frequency of behavioral dyscontrol in some women with borderline personality disorder (30). The patients often reported an enhanced ability to think before acting, a phenomenon referred to as “reflective delay.” This resulted in fewer angry outbursts, episodes of violence, and suicide threats or attempts during the trial period. In contrast, the placebo group showed no such improvements, and seven of eleven placebo patients (64%) were removed from the trial early because of behavioral deterioration, compared with one of fourteen of the carbamazepine trials (7%). In addition, the drug has also proven helpful in the treatment of patients with mixed frontal lobe disease and schizophrenia or schizoaffective disorder with affective or behavioral liability (31).

Carbamazepine is more effective than placebo when used in conjunction with haloperidol in the treatment of excited psychoses of schizophrenic and schizoaffective, as well as manic, patients (32). Because of this apparent efficacy in patients exhibiting more schizophrenic features (22), the effects of carbamazepine on the dopaminergic pathway have been studied by Post et al (33). They found that carbamazepine decreased probenecid-induced CSF accumulation of homovanillic acid (HVA), a dopamine metabolite, and had no effect on baseline CSF concentrations of HVA. This is in contrast to neuroleptics which increase both baseline and probenecid-treated HVA levels in CSF. This, in addition to
the absence of reported cases of tardive dyskinesia, suggests that carbamazepine
does not exert its effect by dopamine receptor blockade. This is consistent with
previous animal studies (34). Rather, the drug may work by decreasing dopa­
mine turnover in the brain. Thus far, carbamazepine has not proven useful in
treating tardive dyskinesia (35).

DRUG INTERACTIONS

Two recent reports have demonstrated that carbamazepine can reduce
plasma levels of haloperidol when the two are administered simultaneously
(36,37). This may be due to hepatic enzyme induction resulting in accelerated
metabolism of haloperidol. Therefore, larger neuroleptic doses may be neces­
sary for the management of patients treated concurrently with carbamazepine.

Another potential complication of carbamazepine treatment is neurotoxic­
ity during coadministration with lithium (38). Patients may present with confu­
sion, drowsiness, weakness, lethargy, coarse tremor, hyperreflexia, nystagmus,
and cerebellar ataxia. These symptoms can be seen in both lithium (39) and
carbamazepine toxicity (40). In this case, however, neurotoxicity may develop at
“nontoxic” plasma levels of each drug. Therefore, monitoring of drug levels
may not protect patients against developing adverse effects. Fortunately the
neurotoxicity is rapidly reversible following discontinuation of treatment. A
history of lithium-induced neurotoxicity is a prominent risk factor for this
complication (38).

On the other hand, coadministration of carbamazepine and lithium offers a
potentially beneficial interaction. Carbamazepine can induce water retention
leading to hyponatremia and water intoxication (41,42). Lithium, on the other
hand, has been used to treat such water retention in SIADH by inducing a
nephrogenic diabetes insipidus (43). These opposite effects on plasma sodium
and fluid balance can offset one another so that patients receiving lithium in
addition to carbamazepine may be less likely to develop hyponatremia than
patients treated with carbamazepine alone (44).

The use of carbamazepine in conjunction with TCA’s and monoamine
oxidase inhibitors (MAOI’s) has not been systematically studied. However, we
can make some inferences on the basis of carbamazepine’s structure and
pharmacology. The drug inhibits presynaptic reuptake of norepinephrine by
approximately 25%, compared to 85% in the case of imipramine (3). Therefore
carbamazepine should be used like other TCA’s and started prior to or at the
same time as MAOI’s when combination therapy is desired (45). Combined
TCA-MAOI treatment, while raising concerns about hypertensive crisis, has
been extensively reviewed and found to be safe and efficacious when adminis­
tered properly (46, 47).

A number of drugs inhibit the metabolism of carbamazepine and may cause
increased serum levels. These include erythromycin, verapamil, diltiazem,
isoniazid, nicotine, and the opiate propoxyphene (4). Through enzyme induc-
USE OF CARBAMAZEPINE FOR PSYCHIATRIC DISORDERS: A REVIEW

Use of carbamazepine decreases serum levels of phenytoin and warfarin as well as doxycycline, sodium valproate, ethosuximide, and clonazepam (3,4).

THEORETICAL CONSIDERATIONS

The efficacy of carbamazepine in the treatment of excited psychoses raises questions about the neurobiology of psychiatric illness. In the late 1960’s it was observed that dominant hemisphere TLE predisposes patients to psychosis, while nondominant hemisphere TLE is associated with bipolar illness (48). This study compared fifty TLE patients with psychotic features with fifty nonpsychotic TLE patients. The presence of psychosis was inversely correlated with seizure activity. A more recent study found that 11 of 17 (65%) of TLE patients and zero of seven generalized epileptics had at least one of the eight Schneiderian first-rank symptoms for schizophrenia (49). Dalbý’s study (1) goes on to demonstrate that TLE patients treated with carbamazepine had markedly reduced affective symptoms such as anxiety, paranoia, and aggressive behavior in 24 of 58 (44%) patients. Moreover, several patients improved psychiatrically despite a lack of seizure control. While nearly half of Dalbý’s epileptic patients had structural brain abnormalities, most subsequent studies of the psychotropic effects of carbamazepine have screened out patients with structural or electroencephalographic abnormalities.

Post et al (50) proposed a theory of agitated psychosis which involved a phenomenon called “kindling.” Repetitive subthreshold stimulation of the limbic system produces a hyperexcitable “kindled” state in which motor seizures may be induced by stimulation that was previously non-seizurogenic. Reviewing the literature on the effects of chronic administration of cocaine and other CNS stimulants, they noted that subjects developed hypersensitivity rather than tolerance to the effects of these substances on pathological behavior and seizures.

Carbamazepine, in addition to phenobarbital and diazepam, is very effective in blocking experimental electrically kindled amygdaloid seizures in a variety of animal species (51). Phenytoin, another potent anticonvulsant, is much less effective in blocking kindled amygdaloid seizures. Moreover, phenytoin exhibits no significant therapeutic effect on manic patients (52). This suggests the possibility of a limbic focus for the generation of mania and other excited psychoses. The mechanism may involve subthreshold kindling of limbic structures. The absence of structural and physiologic abnormalities in such patients could be more reflective of instrumental limitations than the absence of organic pathology.

CONCLUSIONS

Carbamazepine, once used only in the treatment of epilepsy and neuropathic pain, is becoming increasingly important in the treatment of some psychiat-
ric patients, but that group is not yet clearly defined. Because of potential adverse effects and drug interactions, it should be administered judiciously in selected patients who can be carefully monitored. Nevertheless, it is becoming evident that for a certain subset of psychiatric patients, carbamazepine alone or in combination with other drugs may prove to be the only effective treatment that is currently available.

REFERENCES

28. Wehr TA, Goodwin FK: Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psych 36:555–559, 1979